BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32202070)

  • 1. Clinical characteristics of Taiwanese patients with Hereditary spastic paraplegia type 5.
    Chou CT; Soong BW; Lin KP; Tsai YS; Jih KY; Liao YC; Lee YC
    Ann Clin Transl Neurol; 2020 Apr; 7(4):486-496. PubMed ID: 32202070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic analysis of Taiwanese patients with hereditary spastic paraplegia type 5.
    Lan MY; Yeh TH; Chang YY; Kuo HC; Sun HS; Lai SC; Lu CS
    Eur J Neurol; 2015 Jan; 22(1):211-4. PubMed ID: 24641183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5.
    Goizet C; Boukhris A; Durr A; Beetz C; Truchetto J; Tesson C; Tsaousidou M; Forlani S; Guyant-Maréchal L; Fontaine B; Guimarães J; Isidor B; Chazouillères O; Wendum D; Grid D; Chevy F; Chinnery PF; Coutinho P; Azulay JP; Feki I; Mochel F; Wolf C; Mhiri C; Crosby A; Brice A; Stevanin G
    Brain; 2009 Jun; 132(Pt 6):1589-600. PubMed ID: 19439420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exome Sequencing Reveals a Novel Homozygous Frameshift Mutation in the CYP7B1 Gene in a Japanese Patient with SPG5.
    Nan H; Shimozono K; Ichinose Y; Tsuchiya M; Koh K; Hiraide M; Takiyama Y
    Intern Med; 2019 Mar; 58(5):719-722. PubMed ID: 30333426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study.
    Criscuolo C; Filla A; Coppola G; Rinaldi C; Carbone R; Pinto S; Wang Q; de Leva MF; Salvatore E; Banfi S; Brunetti A; Quarantelli M; Geschwind DH; Pappatà S; De Michele G
    J Neurol; 2009 Aug; 256(8):1252-7. PubMed ID: 19363635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White matter lesions in spastic paraplegia with mutations in SPG5/CYP7B1.
    Biancheri R; Ciccolella M; Rossi A; Tessa A; Cassandrini D; Minetti C; Santorelli FM
    Neuromuscul Disord; 2009 Jan; 19(1):62-5. PubMed ID: 19187859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial.
    Schöls L; Rattay TW; Martus P; Meisner C; Baets J; Fischer I; Jägle C; Fraidakis MJ; Martinuzzi A; Saute JA; Scarlato M; Antenora A; Stendel C; Höflinger P; Lourenco CM; Abreu L; Smets K; Paucar M; Deconinck T; Bis DM; Wiethoff S; Bauer P; Arnoldi A; Marques W; Jardim LB; Hauser S; Criscuolo C; Filla A; Züchner S; Bassi MT; Klopstock T; De Jonghe P; Björkhem I; Schüle R
    Brain; 2017 Dec; 140(12):3112-3127. PubMed ID: 29126212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genetic characterization of hereditary spastic paraplegia type 3A in Taiwan.
    Hsu SL; Hsueh HW; Chen SY; Chang YY; Tan S; Hong CT; Tsai YS; Yu KW; Wu HM; Liao YC; Soong BW; Hu CJ; Lan MY; Lee YC
    Parkinsonism Relat Disord; 2021 Jun; 87():87-91. PubMed ID: 34015694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia patient carrying a homozygous Y275X mutation in CYP7B1 (SPG5).
    Hauser S; Höflinger P; Theurer Y; Rattay TW; Schöls L
    Stem Cell Res; 2016 Sep; 17(2):437-440. PubMed ID: 27879220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia patient carrying a homozygous R486C mutation in CYP7B1 (SPG5).
    Höflinger P; Theurer Y; Schüle R; Schöls L; Hauser S
    Stem Cell Res; 2016 Sep; 17(2):422-425. PubMed ID: 27879216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPG5 and multiple sclerosis: clinical and genetic overlap?
    Criscuolo C; Carbone R; Lieto M; Peluso S; Guacci A; Filla A; Quarantelli M; Lanzillo R; Morra VB; De Michele G
    Acta Neurol Scand; 2016 Jun; 133(6):410-4. PubMed ID: 26370385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5.
    Marelli C; Lamari F; Rainteau D; Lafourcade A; Banneau G; Humbert L; Monin ML; Petit E; Debs R; Castelnovo G; Ollagnon E; Lavie J; Pilliod J; Coupry I; Babin PJ; Guissart C; Benyounes I; Ullmann U; Lesca G; Thauvin-Robinet C; Labauge P; Odent S; Ewenczyk C; Wolf C; Stevanin G; Hajage D; Durr A; Goizet C; Mochel F
    Brain; 2018 Jan; 141(1):72-84. PubMed ID: 29228183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phenotype variability in patients with hereditary spastic paraplegia type 5 associated with CYP7B1 mutations.
    Arnoldi A; Crimella C; Tenderini E; Martinuzzi A; D'Angelo MG; Musumeci O; Toscano A; Scarlato M; Fantin M; Bresolin N; Bassi MT
    Clin Genet; 2012 Feb; 81(2):150-7. PubMed ID: 21214876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of CYP7B1 in non-consanguineous cases of hereditary spastic paraplegia.
    Schüle R; Brandt E; Karle KN; Tsaousidou M; Klebe S; Klimpe S; Auer-Grumbach M; Crosby AH; Hübner CA; Schöls L; Deufel T; Beetz C
    Neurogenetics; 2009 Apr; 10(2):97-104. PubMed ID: 18855023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative modeling of 25-hydroxycholesterol-7α-hydroxylase (CYP7B1): ligand binding and analysis of hereditary spastic paraplegia type 5 CYP7B1 mutations.
    Siam A; Brancale A; Simons C
    J Mol Model; 2012 Feb; 18(2):441-53. PubMed ID: 21541746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary spastic paraparesis due to SPG5/CYP7B1 mutation with potential therapeutic implications.
    Pérez-Torre P; García Galloway E; López-Sendón Moreno JL
    Neurologia (Engl Ed); 2023; 38(9):710-711. PubMed ID: 37858890
    [No Abstract]   [Full Text] [Related]  

  • 17. CYP7B1: novel mutations and magnetic resonance spectroscopy abnormalities in hereditary spastic paraplegia type 5A.
    Roos P; Svenstrup K; Danielsen ER; Thomsen C; Nielsen JE
    Acta Neurol Scand; 2014 May; 129(5):330-4. PubMed ID: 24117163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensory ataxia as a prominent clinical presentation in three families with mutations in CYP7B1.
    Di Fabio R; Marcotulli C; Tessa A; Leonardi L; Storti E; Pierelli F; Santorelli FM; Casali C
    J Neurol; 2014 Apr; 261(4):747-51. PubMed ID: 24519355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenoconversion from Spastic Paraplegia to ALS/FTD Associated with
    Theuriet J; Pegat A; Leblanc P; Vukusic S; Cazeneuve C; Millecamps S; Banneau G; Guillaud-Bataille M; Bernard E
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated hydroxycholesterols in Norwegian patients with hereditary spastic paraplegia SPG5.
    Prestsæter S; Koht J; Lamari F; Tallaksen CME; Hoven STJ; Vigeland MD; Selmer KK; Rydning SL
    J Neurol Sci; 2020 Dec; 419():117211. PubMed ID: 33160247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.